HAE 8-K SEC Filing Analysis

Latest settled — T+20d

HAE ▲ +21.17% at T+20d

NEUTRAL call ✓ call won +21.17% · α vs SPY +18.03% · entry $54.37 → $65.88

Next anchor: T+60d in 8w

Last close $74.88 (close Jun 8) · +37.72% from $54.37 entry

Entry anchored
May 7, 2026
via day open

T+1d

+1.38%

call +1.38% · α +0.55%

$55.12

settled 5w ago

T+5d

+4.86%

call +4.86% · α +3.35%

$57.01

settled 27d ago

T+20d

+21.17%

call +21.17% · α +18.03%

$65.88

settled 5d ago

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Haemonetics Q4 FY2026 revenue grew 4.8% YoY to $346.4M, beating estimates, while adjusted EPS of $1.29 edged past consensus. GAAP net loss of $20.1M was driven by a $77.2M impairment of intangible assets from the Attune Medical acquisition. FY2027 guidance calls for 4-7% reported revenue growth and 50-100bps adjusted operating margin expansion, signaling underlying business momentum.

Key Financial Metrics

Guidance

4-7% reported growth

initiated

Free Cash Flow

$44.5M

Gross Margin

57.2%

Actionable Insight

The impairment masks a solid operational quarter. Focus on organic growth acceleration (4.5%) and FY2027 guidance implying mid-single-digit revenue growth and margin expansion. Watch for integration updates on Attune Medical and Vivasure on the earnings call.

Key Facts

Q4 revenue $346.4M, +4.8% YoY; organic revenue growth 4.5%; organic ex-CSL growth 8.6%
Q4 GAAP EPS -$0.44 (net loss $20.1M) vs $1.17 in prior year, due to $77.2M impairment charge
Q4 adjusted EPS $1.29, up 4.0% YoY; adjusted net income $59.7M, down 3.0%
FY2026 full year revenue $1.334B, -2.0% YoY; adjusted EPS $4.96, +8.5%
FY2027 guidance: reported revenue growth 4-7%, organic revenue growth 3-6%, adjusted operating margin expansion 50-100bps
Repurchased $100M in shares in Q4; $325M remaining under $500M authorization

Financial Impact

Non-cash impairment of $77.2M drove GAAP loss; adjusted operations remained profitable with $84.5M adjusted operating income.

gaap net incomeoperating incomefree cash flow

Risk Factors

Integration challenges from Attune Medical and Vivasure acquisitions
Interventional Technologies segment declined 10.3% organic in Q4
Tariff impacts on adjusted gross margin

Market Snapshot

Exchange

NYSE

Sector

Surgical & Medical Instruments & Apparatus

Analyst Consensus

67% bullish (15 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0000313143-26-000031
Document: hae-20260507.htm	0000313143-26-000031
Document: 0000313143-26-000031-index-headers.html	0000313143-26-000031
Document: 0000313143-26-000031-index.html	0000313143-26-000031
Document: 0000313143-26-000031.txt	0000313143-26-000031
8-K Data (Synthetic)	0000313143-26-000031

4 reports for HAE

T+1T+5T+20T+60

Filters

Reports for HAE — sortable, filterable
	Type				Now
Jun 9, 2026 today	DEFA14A NEUTRAL ★ 5/10	—	awaiting T+20	—	—
Jun 5, 2026 4d ago	8-K NEUTRAL ★ 2/10	$70.10 awaiting T+20	awaiting T+20	—	$74.88 (+6.82%)
May 7, 2026 4w ago	8-K NEUTRAL ★ 4/10	$54.37 $65.88	▲ +21.17%	▲ +18.03%	$74.88 (+37.72%)
May 1, 2026 5w ago	8-K NEUTRAL ★ 2/10	$55.32 $67.22	▲ +21.51%	▲ +15.87%	$74.88 (+35.36%)

US Market Status

Market Closed — Opens in 8h 59m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access